Latest price list of Vigabatrin/vigabatrin in 2025
Vigabatrin/vigabatrin is an anti-epileptic drug widely used in epilepsy and other neurological diseases. It is mainly used to treat refractory epilepsy, especially pediatric epilepsy syndromes. Its mechanism of action is to inhibit gamma-aminobutyric acid transaminase, thereby increasing the concentration of gamma-aminobutyric acid (GABA) in the brain, thereby exerting an anticonvulsant effect. Vigabatrin is clinically available in two dosage forms: tablets and oral solutions to meet the needs of different patients.

In the domestic market, the original drug of Vigabatrin has been launched and included in medical insurance, making it easier for many patients to choose medication. Among them, the specifications of the oral solution are 500 mg and 30 bags per box, and the price is about more than 1,000 yuan. This price is relatively acceptable for some patients, especially with the support of the medical insurance reimbursement policy, the financial burden has been reduced. In addition, the price of vigabatrin oral solution dispersible tablets produced in Turkey and other countries, with a specification of 500mg and 100 bags, is also more than 1,000 yuan. These products are also affected by exchange rate changes, so the specific selling price may fluctuate.
In addition to the original drug, generic drugs of vigabatrin have also appeared on the overseas market. Their ingredients are basically the same as the original drug, ensuring the effectiveness of the curative effect. The specifications of this kind of generic drugs are usually 500mg*100 bags, and the price of each box is about 900 yuan. Compared with the original drugs, the price of generic drugs is more affordable and suitable for patients with relatively limited economic conditions.
Overall, Vigabatrin, as an effective anti-epileptic drug, has gradually enriched its market supply. Patients can make reasonable choices based on their own illness, financial status and doctor's recommendations. With the support of medical insurance policies, more and more patients can obtain necessary treatment, which helps improve their quality of life.
Reference materials:https://www.sabril.net/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)